Elucidation of the genetic underpinnings of metastatic colorectal cancer (mCRC) has identified an important role for the epidermal growth factor receptor (EGFR) and the downstream mitogen-activated protein kinase (MAPK) pathways in disease progression leading to the development of multiple targeted therapies for this malignancy. In this regard, the anti-EGFR monoclonal antibodies (mAbs), cetuximab and panitumumab, are important therapeutics in the treatment of mCRC that block MAPK pathway activation by targeting the extracellular domain of EGFR. It is well established that mutations in exons 2, 3, and 4 of the KRAS and NRAS oncogenes (collectively present in ∼50% of mCRC tumours) are predictive of resistance to anti-EGFR mAb therapy ([@bib27]). On this basis, the use of cetuximab and panitumumab is limited to individuals with *RAS* wild-type (WT) tumours in many treatment guidelines ([@bib14]). However, not all *RAS* WT tumours respond to anti-EGFR mAbs, and as the cost of antineoplastic mAb therapy is high and treatment-related toxicity can be considerable, there remains significant scope to identify additional predictive markers of treatment benefit.

Like RAS, the serine/threonine-protein kinase BRAF is a downstream signalling protein in the EGFR-mediated MAPK pathway. The *BRAF* mutant colon cancers appear to be a distinct subset with recognisable clinicopathological characteristics. They often arise from serrated adenomas, occur in the right side of the colon more commonly in women, are high grade in nature, and are strongly associated with defective mismatch repair ([@bib11]; [@bib7]). As with *RAS* mutations, mutation of codon 600 in the activation segment of the *BRAF* gene (*BRAF* MT) causes constitutive activation of the MAPK pathway, and is implicated as a source of impaired response to anti-EGFR mAbs in patients with mCRC ([@bib1]; [@bib3]; [@bib4]; [@bib6]; [@bib10]; [@bib12]; [@bib13]; [@bib18]; [@bib23]; [@bib30]). Notably, a meta-analysis of data from observational studies has provided evidence that *BRAF* MT is associated with a poor prognosis (i.e., negative prognostic biomarker) in mCRC ([@bib33]). Based on preclinical studies ([@bib20]) that demonstrated synergistic activities between EGFR mAb and *BRAF* inhibitors/MEK inhibitors, clinical trials are ongoing that evaluate alternate approaches such as the addition of the triple chemotherapy regimen (oxaliplatin+irinotecan+5-Fluorouracil), BRAF inhibitors, and MEK inhibitors to anti-EGFR mAb therapy regimens ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)---NCT01902173, NCT02164916). However, whether *BRAF* MT also causes resistance to anti-EGFR mAb therapy (i.e., is a predictive biomarker) is currently uncertain. This study undertook a systematic review and meta-analysis of randomised controlled trial (RCT) data to quantitatively evaluate the evidence for *BRAF* MT as a negative predictive biomarker for efficacy of anti-EGFR mAb therapy in mCRC.

Materials and Methods
=====================

Study eligibility criteria
--------------------------

Studies were eligible if they were RCTs in which treatment with an anti-EGFR antibody, either alone or combined with standard therapy, had been compared with the same standard therapy for patients with mCRC. In addition, tumours must have been assessed for *BRAF* mutation status (*BRAF* WT or *BRAF* MT) as a subset of the *RAS* (minimally *KRAS* exon 2 and 3) WT subgroup, and studies had to have follow-up data on overall survival (OS) or progression-free survival (PFS) outcomes. Studies were excluded if they did not provide sufficient quantitative data of the anti-EGFR treatment effect according to *BRAF* and *RAS* mutation status.

Search strategy and identification of studies
---------------------------------------------

Embase, Medline, and Web of Science were searched until 25 July 2014 for the following terms: (colon cancer or colorectal cancer or colon carcinoma or metastatic colorectal cancer or mCRC) and (BRAF or B-RAF or B RAF) and (anti-EGFR or EGF or epidermal growth factor receptor or monoclonal antibody/ies or MoAb or mAb or cetuximab or panitumumab). Relevant MeSH (Medline) or Emtree (Embase) terms were used where possible. Differences in truncation symbols and wildcards between databases were considered. No restrictions were placed on the searches. Duplicate citations were removed. The titles and abstracts of all remaining citations were reviewed and irrelevant citations were discarded. Potentially relevant studies were retrieved in full text and assessed to determine whether they matched the study eligibility criteria. Hand searches of the reference lists of the relevant reports were carried out to identify any relevant studies that were missed with the search strategy. If multiple reports referred to the same data, the report containing the (largest and) most recent data was included in the review, and these data were cross-checked against the other reports. Review of papers for inclusion was undertaken independently by two investigators (MMD and MDW) with any discrepancies resolved by the other investigators (MJS and AR).

Assessment of study risk of bias
--------------------------------

An assessment of the methodological quality of the studies included in meta-analyses was based on guidance for the evaluation of the conduct of biomarker studies that use archived tumour specimens ([@bib25]; [@bib15]). For each included pharmacogenomic substudy of a RCT, four domains were used to assess the risk of bias (high, moderate, or low): (1) biomarker sample ascertainment, (2) assay analytical performance, (3) prespecified analysis plan, and (4) parent RCT. Studies were assigned a low risk of bias for each respective domain if the biomarker status was ascertained in a sufficiently large proportion of original study participants and/or the sample population used for the biomarker analysis was demonstrated to be sufficiently representative of the originally enrolled study population, the assay had been analytically validated for use with archived tissue and the assay was performed blinded to the clinical data, an analysis plan for the biomarker study was prepared before biomarker testing or analysis of the biomarker results, and the parent RCT was of low risk of bias.

Statistical analysis
--------------------

The hazard ratio was used to represent the comparative treatment effect on survival outcomes for anti-EGFR mAb therapy compared with no anti-EGFR mAb therapy. Included studies generally reported hazard ratios derived from Cox proportional-hazards models stratified according to randomisation factors (e.g., Eastern Cooperative Oncology Group (ECOG) performance status). If the hazard ratio for a *BRAF* subgroup was not reported, the value was estimated where possible by combining smaller subgroups with a fixed-effect meta-analysis. Summary estimates of anti-EGFR mAb treatment effect hazard ratios for *BRAF* MT and *BRAF* WT tumours were pooled separately using a random-effects model based on the inverse variance method. Evidence for treatment effect modification (i.e., a predictive biomarker) by *BRAF* mutation status was evaluated by a test of interaction. Specifically, a random-effects meta-analysis of the interaction hazard ratio (hazard ratio for *BRAF* MT tumours divided by the hazard ratio for *BRAF* WT tumours) was calculated for each study. Exploratory analyses were undertaken to evaluate whether the line of therapy (i.e., first or subsequent line) for use of anti-EGFR mAb was associated with a differential impact of *BRAF* mutations on anti-EGFR mAb efficacy. The primary analyses were repeated by stratifying the trials according to first-line *vs* non-first-line anti-EGFR mAb use.

Heterogeneity between studies was assessed using the Cochrane\'s *Q* statistic and *I*^2^ statistic. Small-study effects (and risk of publication bias) were assessed by visual inspection of funnel plots and Egger\'s linear regression test. All reported *P*-values are two sided. Analyses were carried out with R 3.0.0 (The R Foundation for Statistical Computing, Vienna, Austria).

Results
=======

Overview of included studies and assessment of study quality
------------------------------------------------------------

Biomarker analyses of eight RCTs published in seven study reports were included in the systematic review ([Figure 1](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}) ([@bib2]; [@bib5]; [@bib17]; [@bib24]; [@bib26]; [@bib8]; [@bib16]). Of the 3168 participants with *RAS* WT tumours across the 8 RCT substudies, 2817 harboured *BRAF* WT and 351 (11.1%) *BRAF* MT tumours. All studies compared the addition of an anti-EGFR agent with background therapy, four evaluated cetuximab and four assessed panitumumab. Five studies restricted the analysis to *KRAS* WT tumours and two restricted analyses to *KRAS* WT and *NRAS* WT tumours. For the COIN study, analysis of PFS according to *RAS* status was defined based on both *KRAS* and *NRAS* mutations, whereas *RAS* status for OS was based on *KRAS* mutations only. [Table 1](#tbl1){ref-type="table"} summarises details of background therapy, lines of treatment, *RAS* WT, and *BRAF* mutation status. Hazard ratios were typically adjusted for performance status, and the substudies of the CO.17 and PICCOLO trials adjusted the hazard ratio for a broader range of baseline characteristics. The risk of bias was generally similar between studies included in meta-analyses with respect to each of the four domains ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

Effect of BRAF mutation on OS benefit with anti-EGFR mAbs
---------------------------------------------------------

Based on the pharmacogenomic substudies of 7 RCTs, the hazard ratio for OS benefit with anti-EGFR mAb therapy was 0.97 (95% CI; 0.67--1.41) for *RAS* WT/*BRAF* MT tumours as compared with 0.81 (95% CI; 0.70--0.95) for *RAS* WT/*BRAF* WT tumours ([Figure 2](#fig2){ref-type="fig"}). However, the difference between *RAS* WT/*BRAF* MT and *RAS* WT/*BRAF* WT tumours with respect to the OS benefit of anti-EGFR mAb therapy was not statistically significant (test of interaction; *P*=0.43). Visual inspection and regression tests (*P*=0.97) did not indicate any significant relationship between study size and the test of interaction (i.e., publication bias).

Effect of BRAF mutation on PFS benefit with anti-EGFR mAbs
----------------------------------------------------------

Based on the pharmacogenomic substudies of 8 RCTs, the hazard ratio for PFS benefit with anti-EGFR mAb therapy was 0.86 (95% CI; 0.61--1.21) for *RAS* WT/*BRAF* MT tumours as compared with 0.62 (95% CI; 0.50--0.77) for *RAS* WT/*BRAF* WT tumours ([Figure 3](#fig3){ref-type="fig"}). The difference between *RAS* WT/*BRAF* MT and *RAS* WT/*BRAF* WT tumours with respect to the PFS benefit of anti-EGFR mAb therapy was not statistically significant (test of interaction; *P*=0.07). Visual inspection and regression tests (*P*=0.63) did not indicate any significant relationship between study size and the test of interaction (i.e., publication bias).

Impact of line of therapy
-------------------------

In an exploratory analysis restricted to first-line anti-EGFR mAb therapy, little difference was observed between *RAS* WT/*BRAF* WT and *RAS* WT/*BRAF* MT tumours with respect to either OS efficacy (hazard ratio 0.87 *vs* 0.89, *P*=0.96, [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}) or PFS efficacy (hazard ratio 0.75 *vs* 0.83, *P*=0.45, [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). For non-first-line anti-EGFR mAb therapy there were nonstatistically significant trends towards a difference in efficacy between *RAS* WT/*BRAF* WT and *RAS* WT/*BRAF* MT tumours with respect to OS (hazard ratio 0.74 *vs* 1.06, *P*=0.38, [Supplementary Figure 3](#sup1){ref-type="supplementary-material"}) and PFS (hazard ratio 0.53 *vs* 0.84, *P*=0.05, [Supplementary Figure 4](#sup1){ref-type="supplementary-material"}).

Discussion
==========

This meta-analysis of pharmacogenomic substudies from eight RCTs highlights that based on the standard approach for assessing predictive markers there is insufficient evidence to conclusively demonstrate that the presence of *BRAF* mutation is a negative predictive biomarker of benefit from the use of anti-EGFR mAbs in *RAS* WT mCRC.

We believe that this is the first meta-analysis to systematically and quantitatively summarise the evidence from RCTs in line with current methodological guidelines ([@bib21]; [@bib9]; [@bib28]) with respect to the predictive value of *BRAF* MT for survival benefit of anti-EGFR mAb therapy in *RAS* WT tumours. Previous meta-analyses of observational studies have demonstrated that *BRAF* MT is a negative prognostic biomarker ([@bib22]; [@bib31]; [@bib32]; [@bib33]; [@bib29]), but this is distinct from assessing whether *BRAF* MT modifies the treatment effect of anti-EGFR mAbs (i.e., predictive biomarker). A prior study based on pooled data from the CRYSTAL and OPUS trials (*n*=800) evaluated the impact of *BRAF* MT on the survival benefit associated with cetuximab use for *RAS* WT mCRC tumours ([@bib2]), and concluded that there were no significant differences in outcome between the treatment groups. The inclusion of data from six additional RCTs in the current review provides a greater representation of the heterogeneity in the uncertainty regarding the impact of *BRAF* MT on treatment effect. The current meta-analysis includes studies where participants were administered panitumumab and cetuximab, different lines of therapy, and a range of background chemotherapy.

Recently, a meta-analysis reported the efficacy of anti-EGFR mAb treatment of mCRC with a *BRAF* mutation, and concluded that anti-EGFR mAb therapy did not provide benefit in this subgroup ([@bib19]). The current study differs from this recent meta-analysis in terms of the statistical methods of analysis and inclusion criteria. Instead of simply estimating anti-EGFR mAb efficacy in the *BRAF* MT subgroup, the current study focussed on assessing whether anti-EGFR mAb efficacy differs based on *BRAF* mutation status (i.e., consideration of whether subgroup differences may be caused by chance alone). Guidelines for undertaking subgroup analysis of RCTs (i.e., identifying a predictive marker) clearly indicate that it is the treatment effect interaction between subgroups, rather than the treatment effect of within an individual subgroup, that should primarily be interpreted when deriving a conclusion as to whether the factor/marker influences the treatment effect ([@bib21]; [@bib9]; [@bib28]). As [@bib19]) only evaluated a single subgroup (*BRAF* MT), the conclusions of this study regarding the predictive value of *BRAF* mutation status are not valid based on guideline recommendatons. An additional contrast to the recent meta-analysis is that the current meta-analysis excluded trials comparing anti-EGFR mAb therapy with bevacizumab on the basis that they are not sufficiently comparable to the other included trials. For example, a hazard ratio of 1 in a trial of standard therapy±anti-EGFR mAb indicates a lack of efficacy, but the same hazard ratio in a trial of standard therapy+anti-EGFR mAb or bevacizumab indicates a significant benefit as bevacizumab use is associated with a significant benefit.

The contrasting conclusions of these meta-analyses highlight important ongoing challenges with respect to undertaking subgroup analysis to identify predictive markers of treatment effect. The approach specified in current guidelines (as undertaken in the present analysis) aim to control the risk of falsely concluding a difference in treatment effect between subgroups (i.e., to minimise risk of false positive results) by undertaking a test of interaction and controlling for multiplicity of tests. In this paradigm, a marker will only be considered predictive when there is relatively strong evidence that the differences in treatment effect observed for the subgroups are unlikely to be due to chance alone. Hence, such an approach is often poorly powered to detect real subgroup differences and the risk of false negative results is high. The current analysis shows that even with pooled data from substudies of seven to eight RCTs, analyses may still be insufficiently powered to detect predictive biomarkers. In particular, it is likely to be difficult to conclusively demonstrate the validity of predictive markers with low prevalence and markers that predict partially attenuated response to therapy (compared with markers that predict either no or reversal of effect).

Although finding predictive biomarkers that identify individuals who have no (or deleterious) response to therapy is particularly important, for high cost and/or toxic drugs, such as anti-EGFR mAbs, identification of individuals with reduced efficacy may also be of value. For example, if it was confirmed that individuals with *RAS* WT/*BRAF* MT tumours receive some, but significantly reduced, benefit from anti-EGFR mAbs compared with *RAS* WT/*BRAF* WT tumours, clinician and patient decisions regarding the use of anti-EGFR mAbs in mCRC may be influenced. It could also substantially impact the cost effectiveness of the anti-EGFR mAb therapy for *RAS* WT/*BRAF* MT tumours, and hence the subsidy decisions in some jurisdictions.

The current study highlights that there is currently insufficient evidence to mandate the clinical application of *BRAF* MT status in *RAS* WT mCRC to determine eligibility for access to anti-EGFR mAb therapy. In the absence of additional data providing a conclusive outcome, consideration of *BRAF* mutation status when evaluating the role of anti-EGFR mAbs as a therapeutic option in patients with mCRC should remain at the discretion of the treating physician and patient, and be considered in the context of each patient\'s circumstance (e.g., access to alternate therapeutic options, predisposition to toxicity, frailty), recognising that there remains a reasonable possibility that chance alone may explain the differences in anti-EGFR mAb efficacy observed between *BRAF* mutation subgroups.

Because of the small sample size of the *RAS* WT/*BRAF* MT tumours in all trials (*n*\<75 for each), there is the risk of a chance imbalance in important prognostic factors despite randomisation of participants to the treatment arms. For this reason, it may be of value to adjust for potential differences in important baseline characteristics between treatment groups. Most of the substudies included adjustment for only performance status. In contrast, the substudy of the CO.17 trial adjusted for a range of baseline characteristics including baseline lactate dehydrogenase level, number of disease sites, number of previous chemotherapy drug classes, primary tumour site, and presence of liver metastases. Whether the hazard ratios reported for the other studies would differ significantly if adjusted for a wider range of prognostic factors is unknown.

The current study focussed specifically on survival outcomes. However, it may be worthwhile to evaluate Response Evaluation Criteria in Solid Tumours (RECIST response) as an additional outcome. Although response rate is not as clinically meaningful as are survival outcomes, such an analysis may be better powered to detect the impact of *BRAF* MT on anti-EGFR mAb efficacy (i.e., the interaction between *BRAF* mutation status and the odds ratio of response due to anti-EGFR mAb therapy for *RAS* WT tumours). It will be useful to assess in future studies whether attenuation in efficacy relates primarily to a reduced likelihood of achieving and/or a more modest depth/duration of response. It was not possible to evaluate response rate in the current study as response data were only reported according to *BRAF* and *RAS* mutation status in the publications of the CRYSTAL and OPUS trials. An important direction for future research will be to undertake a patient-level meta-analysis of these studies that includes a more consistent and extensive assessment of the value of adjusting for potential baseline imbalances between treatments in the *RAS* WT/*BRAF* MT subgroup.

In conclusion, based on the data from the pharmacogenomic substudies of eight RCTs, there is currently insufficient evidence to definitively consider *BRAF* MT a negative predictive biomarker of survival benefit from anti-EGFR mAb therapy for mCRC. The benefit in OS and PFS for *BRAF* MT tumours treated with anti-EGFR mAb therapy may be smaller or less likely, but further data are required to clarify this observation. This systematic review highlights that current evidence does not support mandatory clinical application of *BRAF* MT status of *RAS* WT mCRC to determine eligibility for access to anti-EGFR mAb therapy.
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![**Forest plot of the overall survival benefit with anti-EGFR mAb therapy for subgroups defined by tumour *RAS* and *BRAF* mutations.** Cmab=cetuximab; MT=mutant; Pmab=panitumumab; WT=wild type.](bjc2015173f2){#fig2}

![**Forest plot of the progression-free survival benefit with anti-EGFR mAb therapy for subgroups defined by tumour *RAS* and *BRAF* mutations.** Cmab=cetuximab; MT=mutant; Pmab=panitumumab; WT=wild type.](bjc2015173f3){#fig3}

###### Summary of studies included in meta-analyses

                                                                                                                                     **Proportion of study participants**                                   
  --------------------------------- ---------------------------- ----------------------------------------------------------- ------ -------------------------------------- ---------- ----------- --------- ----------
  Cetuximab *vs* no cetuximab             CO.17 ([@bib8])                             BSC, ⩾second line                       572                     NR                    208 (36)   208 (100)   10 (5)    Adjusted
                                     CRYSTAL and OPUS ([@bib2])       FOLFIRI (CRYSTAL) or FOLFOX-4 (OPUS), first line        1535                1378 (90)                 845 (55)   800 (95)    70 (8)    Adjusted
                                          COIN ([@bib26])         Oxaliplatin and fluoropyrimidine chemotherapy, first line   2445                1949 (80)                 729 (30)   671 (92)    90 (12)      NR
  Panitumumab *vs* no panitumumab       20020408 ([@bib17])                           BSC, ⩾third line                        463                  288 (62)                 153 (33)   130 (85)    15 (10)   Adjusted
                                        20050181 ([@bib16])                         FOLFIRI, second line                      1186                1014 (85)                 421 (35)   421 (100)   45 (11)      NR
                                         PICCOLO ([@bib24])                       Irinotecan, ⩾second line                    696                     NR                    460 (66)   439 (95)    68 (15)   Adjusted
                                          PRIME ([@bib5])                           FOLFOX-4, first line                      1183                1060 (90)                 512 (43)   499 (97)    53 (10)   Adjusted

Abbreviations: *BRAF* MT=*BRAF* mutant; BSC=best supportive care; EGFR=epidermal growth factor receptor; FOLFIRI=folinic acid, fluorouracil, irinotecan; FOLFOX-4=folinic acid, fluorouracil, oxaliplatin; HR=hazard ratio; ITT=overall intention-to-treat population; NR=not reported in the publication; *RAS* WT=*RAS* wild type; ≥second: second or higher line treatment, ≥third: third or higher line treatment.

The proportion of the original clinical trial participants that were evaluable for *KRAS* (CO.17, CRYSTAL, OPUS, COIN, 20020408, and PICCOLO) or *RAS* (20050181 and PRIME) mutation analysis.

The proportion of the original clinical trial participants for which *KRAS* (CO.17, CRYSTAL, OPUS, COIN, 20020408, and PICCOLO) or *RAS* (20050181 and PRIME) WT status was ascertained.

The proportion of the *KRAS* (CO.17, CRYSTAL, OPUS, COIN, 20020408, and PICCOLO) or *RAS* (20050181 and PRIME) WT group for which a *BRAF* -- WT or MT -- mutation status was ascertained.

The proportion of the *KRAS* (CO.17, CRYSTAL, OPUS, COIN, 20020408, and PICCOLO) or *RAS* (20050181 and PRIME) WT group for which a *BRAF* MT status was ascertained.

Whether the predictive analysis HR values presented in the publication for overall survival (OS) and progression-free survival (PFS), in the *RAS* WT subgroup according to *BRAF* mutation status (WT or MT), were adjusted or unadjusted (variables adjusted for: *CO.17 trial*: Eastern Cooperative Oncology Group (ECOG) performance status, gender, age, baseline lactate dehydrogenase level, baseline alkaline phosphatase, baseline haemoglobin, number of disease sites, number of previous chemotherapy drug classes, primary tumour site, and presence of liver metastases; *CRYSTAL and OPUS trials*: ECOG performance status; *20020408 trial*: ECOG performance status and geographic region; *PICCOLO trial*: centre, World Health Organisation (WHO) performance status, previous oxaliplatin, previous bevacizumab, previous dose modifications, and best previous response to therapy; *PRIME trial*: ECOG performance status and geographic region).
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